Anti-obesity drugs to command a $44 billion market by 2030

As obesity rates continue to soar across the globe, analysts anticipate that the market for anti-obesity drugs will skyrocket in the coming years. Goldman Sachs projects the market to be worth $44 billion by 2030. That’s an almost 16-fold expansion from its valuation of approximately $2.82 billion in 2022.

Jenny Chang, portfolio manager with Goldman Sachs Asset Management, highlighted the potential of the drug class, which includes Novo Nordisk’s Ozempic (semaglutide) and Wegovy (also semaglutide), as well as Eli Lilly’s tirzepatide. “Some 42% of Americans are obese, and the economic toll is staggering,” she said in a recent video. The investment firm noted that obesity costs the American healthcare system are in the ballpark of $170 billion annually. Furthermore, the obesity epidemic could drag down global GDP by $4 trillion by 2035.

Echoing this sentiment, JPMorgan Chase & Co. believes Novo Nordisk could capture almost half o…

Read more
  • 0